Automated Analyzers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Analyzer (Biochemistry Analyzers, Immuno-based Analyzers, Hematology Analyzers), By Application (Drug Discovery, Genomics, Proteomics, Bioanalysis, Analytical Chemistry, Clinical Diagnostics), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 8.59 Billion
CAGR (2026-2031)	6.04%
Fastest Growing Segment	Immuno-based Analyzers
Largest Market	North America
Market Size (2031)	USD 12.21 Billion

Market Overview

The Global Automated Analyzers Market will grow from USD 8.59 Billion in 2025 to USD 12.21 Billion by 2031 at a 6.04% CAGR. Automated analyzers are high-throughput laboratory instruments designed to process biological samples and perform diagnostic assays with minimal human intervention, utilizing varied technologies such as photometry, immunoassays, and chromatography. The market is primarily supported by the escalating global prevalence of chronic diseases and an aging population, which collectively necessitate higher volumes of diagnostic testing. Furthermore, a persistent shortage of skilled laboratory professionals compels healthcare facilities to adopt automation to maintain operational efficiency and ensure rapid result turnaround times.

However, a significant challenge impeding broad market expansion is the substantial capital investment required to implement these complex systems, which poses a financial barrier for smaller, resource-constrained laboratories. This economic strain is often exacerbated by rigorous regulatory requirements that prolong product approval timelines. To illustrate the sector's magnitude, according to MedTech Europe, in 2024, the European medical technology market was estimated at approximately €170 billion. This figure highlights the substantial economic scale of the industry in which diagnostic automation plays an essential role.

Key Market Drivers

The rising prevalence of chronic and infectious diseases stands as a primary catalyst for the Global Automated Analyzers Market, fundamentally increasing the volume of diagnostic tests required. As conditions like cardiovascular disorders and cancer become more widespread, laboratories face pressure to process samples with greater speed, compelling the adoption of high-throughput automated analyzers. According to the World Health Organization, May 2024, in the 'World Health Statistics 2024' report, noncommunicable diseases continued to account for 74% of all deaths globally, underscoring the need for robust diagnostic infrastructure. Illustrating the massive operational scale this burden creates, according to Roche, February 2024, in the 'Annual Report 2023', the company delivered approximately 29 billion diagnostic tests to customers worldwide in 2023.

Simultaneously, the persistent shortage of skilled laboratory professionals drives the integration of automation to bridge the gap between testing capacity and available workforce. Laboratories rely on automated systems to perform repetitive tasks, mitigating the impact of vacancies and preventing burnout. This transition is essential for sustaining operations despite a shrinking talent pool. According to the American Society for Clinical Pathology, January 2024, in the '2022 Vacancy Survey' results, retirement rates for laboratory professionals have doubled compared to pre-pandemic projections, exacerbating the workforce crisis. Consequently, automation has shifted to a strategic necessity, allowing facilities to maintain efficiency without expanding headcount.

Download Free Sample Report

Key Market Challenges

The high capital investment required for automated analyzers constitutes a formidable barrier to market entry and expansion, particularly for small to medium-sized laboratories. These systems involve substantial upfront costs for acquisition, installation, and personnel training, which can severely strain the budgets of resource-limited healthcare facilities. Consequently, many potential buyers are forced to delay procurement or continue using legacy equipment, thereby slowing the adoption rate of advanced automation technologies and directly dampening overall market growth. This financial hurdle effectively segments the market, restricting the most advanced high-throughput solutions to large, well-funded institutions while leaving a significant portion of the diagnostic sector underserved.

The impact of this economic constraint is intensified by the prevailing financial instability within the healthcare provider sector, which further limits capital expenditure capabilities. According to the American Hospital Association, in 2024, hospitals and health systems reported a 28.3% decrease in days cash on hand compared to levels observed in 2022. This liquidity crunch restricts the ability of these facilities to allocate funds for expensive capital equipment like automated analyzers, creating a direct impediment to new sales and hampering the broader expansion of the global market.

Key Market Trends

The Integration of Artificial Intelligence and Machine Learning for Workflow Optimization is fundamentally reshaping the Global Automated Analyzers Market by embedding predictive capabilities directly into diagnostic platforms. Laboratories are increasingly deploying AI-driven algorithms to enhance result accuracy, automate sample validation, and enable predictive maintenance, which significantly reduces unplanned instrument downtime. This technological evolution allows facilities to maximize the utility of generated data, moving beyond simple processing to intelligent workflow management that ensures consistent operational resilience. The regulatory landscape explicitly reflects this surge in innovation, as authorities accelerate the approval of smart diagnostic tools. According to MedTech Dive, October 2024, in the 'The number of AI medical devices has spiked in the past decade' article, the U.S. Food and Drug Administration authorized 221 artificial intelligence or machine learning-enabled medical devices in 2023, highlighting the rapid commercialization of these intelligent systems.

Concurrently, there is a decisive Shift Towards Miniaturized and Portable Point-of-Care Automated Analyzers, driven by the industry's move toward decentralized testing. Healthcare providers are adopting compact, multiplex platforms that deliver rapid, central-lab-quality results in emergency departments and non-hospital settings, thereby reducing the logistical dependency on core laboratories. This trend focuses on speeding up clinical decision-making through advanced molecular and immunoassay technologies that have been successfully scaled down for near-patient use. The market's strong reception to these agile solutions is evident in the robust adoption rates of newly launched compact systems. According to bioMérieux, March 2024, in the '2023 Financial Results' report, the company reported the installation of close to 400 new BIOFIRE SPOTFIRE point-of-care instruments in the fourth quarter of 2023 alone, underscoring the accelerating uptake of these miniaturized diagnostic technologies.

Segmental Insights

The immuno-based analyzers segment represents the fastest-growing category within the global automated analyzers market. This growth is driven by the increasing prevalence of infectious and chronic diseases, which creates urgent demand for high-volume diagnostic testing. Laboratories favor these systems for their ability to deliver rapid and precise detection of antibodies and antigens. Additionally, the sector is supported by rigorous product clearances from regulatory bodies like the US Food and Drug Administration, which instills confidence in clinical settings regarding the safety and performance of these diagnostic platforms.

Regional Insights

North America maintains a dominant position in the Global Automated Analyzers Market, supported by an advanced healthcare infrastructure and the concentration of key industry players. The region's extensive adoption of laboratory automation effectively addresses the growing burden of chronic diseases and the need for efficient diagnostic workflows. Furthermore, a stable regulatory framework, reinforced by the U.S. Food and Drug Administration (FDA) and the quality standards of the Centers for Medicare & Medicaid Services (CMS), fosters product reliability and clinical acceptance. This strategic combination of technological integration and regulatory oversight solidifies North America’s market leadership.

Recent Developments

• In October 2024, Siemens Healthineers unveiled the Atellica Integrated Automation solution, embedded directly within the Atellica CI Analyzer to consolidate manual tasks and streamline laboratory operations. This new offering was designed to automate approximately twenty-five distinct manual workflows, including sample management, decapping, and sealing, which are typically performed by laboratory staff. By integrating these automation capabilities into a standalone analyzer, the company aimed to make high-volume automation features accessible to smaller laboratories with limited space. The solution reportedly reduces manual workflow steps by significantly decreasing the need for physical sample handling, thereby allowing staff to focus on higher-value clinical activities.
• In July 2024, Beckman Coulter Diagnostics introduced the DxC 500i Clinical Analyzer, an integrated system combining clinical chemistry and immunoassay capabilities for satellite and core laboratories. This launch provided healthcare networks with a scalable solution that utilizes common reagents and consumables, ensuring consistent patient results across different testing locations. The analyzer incorporates the technology of the previously released DxC 500 AU Chemistry Analyzer, offering Six Sigma performance and onboard guided workflows to enhance operational efficiency. Designed to support hub-and-spoke laboratory models, the DxC 500i aims to improve inventory management and streamline patient care delivery within integrated health systems.
• In June 2024, Roche announced the commercial availability of its new cobas c 703 and cobas ISE neo analytical units for the cobas pro integrated solutions in markets accepting the CE mark. These latest additions were engineered to address laboratory challenges such as staff shortages and space constraints by significantly increasing testing capacity and automation. The cobas c 703 unit doubles the clinical chemistry throughput of previous models, offering up to 2,000 tests per hour with 70 reagent positions. The cobas ISE neo unit improves electrolyte testing efficiency through automated maintenance, thereby reducing manual hands-on time for laboratory operators.
• In January 2024, Horiba Medical launched the HELO 2.0, a high-throughput automated hematology platform designed to enhance efficiency in mid- to large-scale laboratories. This integrated solution, which obtained CE-IVDR approval, features the Yumizen H2500 and H1500 analyzers and offers flexible configurations for standalone or track-based setups. The system incorporates updated technologies such as 360-degree sample mixing and automated quality control transfer to optimize workflow and reduce turnaround times. Additionally, the platform addresses pre- and post-analytical needs including tube management and blood smear digitalization, supporting improved sample handling and laboratory accreditation requirements.

Key Market Players

• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Hudson Robotics Inc.
• Becton Dickinson and Company
• Synchron
• Agilent Technologies Inc.
• Siemens Healthineers AG
• Tecan Trading AG
• PerkinElmer Inc.
• Honeywell International Inc.

By Analyzer	By Application	By Region
Biochemistry Analyzers Immuno-based Analyzers Hematology Analyzers	Drug Discovery Genomics Proteomics Bioanalysis Analytical Chemistry Clinical Diagnostics	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Automated Analyzers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Automated Analyzers Market, By Analyzer:

• Biochemistry Analyzers
• Immuno-based Analyzers
• Hematology Analyzers

• Automated Analyzers Market, By Application:

• Drug Discovery
• Genomics
• Proteomics
• Bioanalysis
• Analytical Chemistry
• Clinical Diagnostics

• Automated Analyzers Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE